Abstract Number: 0589 • ACR Convergence 2023
A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE
Background/Purpose: We have shown that serum IgA2 anti-dsDNA antibody levels is a biomarker of response to belimumab after rituximab in SLE (BEAT-lupus trial) (1). We…Abstract Number: 2124 • ACR Convergence 2023
Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals
Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis.…Abstract Number: 0607 • ACR Convergence 2023
CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained
Background/Purpose: We have previously shown that CD19 CAR T cell therapy leads to stable drug-free remission of treatment-resistant SLE (1,2). Based on these findings we…Abstract Number: 2189 • ACR Convergence 2023
Lymphopenia Fluctuation Patterns Determine the Trajectory of the Disease in Sjogren’s Patients with Hematological Involvement
Background/Purpose: Sjogren's disease (SjD) is characterized by a moderate prevalence of cytopenia, mainly neutropenia and lymphocytopenia with a typical fluctuating pattern. The associations between clinical…Abstract Number: 0728 • ACR Convergence 2023
Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype
Background/Purpose: Systemic lupus erythematous (SLE) is a heterogenous autoimmune disorder characterized by pathogenic antinuclear antibodies. An interferon (IFN) gene signature and B cell aberrations are…Abstract Number: 2341 • ACR Convergence 2023
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
Background/Purpose: Belimumab (BLM) is a monoclonal antibody that inhibits B-lymphocyte stimulating factor (BlyS), approved in 2011 as a treatment for systemic lupus erythematosus (SLE). We…Abstract Number: 0152 • ACR Convergence 2022
Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome
Background/Purpose: CD19 is considered a canonical B cell lineage marker. Previously, we have reported that CD19+CD21lo/negCD11c+ cells were increased in both systemic sclerosis [PMC8828801] as…Abstract Number: 0784 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
Background/Purpose: Immunocompromised patients with immune mediated inflammatory diseases (IMIDs) undergoing therapy with B cell depleting agents (BCDT) are among the most vulnerable to severe COVID-19…Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…Abstract Number: 0159 • ACR Convergence 2022
B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab
Background/Purpose: Recent observations suggest the importance of the BAFF pathway in the pathogenesis of Idiopathic Inflammatory Myositis (IIM). Elevated serum levels of circulating BAFF in…Abstract Number: 0979 • ACR Convergence 2022
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
Background/Purpose: Mucocutaneous manifestations affect >80% of patients (pts) with SLE and can contribute to their poor quality of life through unwanted attention, self-consciousness, emotional symptoms,…Abstract Number: 2183 • ACR Convergence 2022
mTORC2 Contributes to Murine Systemic Autoimmunity
Background/Purpose: The development of many systemic autoimmune diseases, including systemic lupus erythematosus, is associated with overactivation of the type I interferon (IFN) pathway, lymphopenia, and…Abstract Number: 0506 • ACR Convergence 2022
Immunophenotypic Categorization of Systemic Immune-mediated Diseases
Background/Purpose: Systemic immune-mediated diseases are heterogeneous, and the pathogenesis varies among and within each disease. Some studies tried to stratify patients with immune-mediated diseases into…Abstract Number: 0987 • ACR Convergence 2022
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor necrosis factor (TNF) superfamily members that bind TACI (transmembrane activator and CAML…Abstract Number: 0600 • ACR Convergence 2022
Correlates Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Phenotypes: Data from the Accelerated Medicines Partnership
Background/Purpose: Prior studies have characterized the diverse cell types in the RA synovium through a multi-center consortium incorporating RNA-seq data. Due to the novelty of…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 12
- Next Page »